Epitalon.

Targeting senescent cells, telomere maintenance, and NAD+ availability.

Cellular senescence is a state in which a damaged cell permanently stops dividing but does not die. Senescent cells accumulate with age and secrete a mix of inflammatory cytokines, proteases, and growth factors collectively called the senescence-associated secretory phenotype, which is thought to drive chronic low-grade inflammation in surrounding tissue. Clearing these cells in animal models has been associated with improvements in several age-related measures, which is the entire premise behind senolytic compounds. One compound here exploits a specific vulnerability. In senescent cells the transcription factor FOXO4 accumulates and binds the tumour suppressor p53, holding it in the nucleus and preventing it from triggering apoptosis. That interaction is what keeps a damaged cell alive when it should have died. A retro-inverso peptide designed to disrupt the FOXO4 and p53 interface frees p53 to initiate intrinsic apoptotic signalling. Because healthy cells do not depend on this interaction for survival, the effect is proposed to be selective for senescent cells. A second approach targets telomere maintenance. Telomeres shorten with each cell division until a cell reaches its replicative limit, and telomerase is the enzyme that can extend them. A short peptide in this group has been reported in cultured human cells to induce telomerase expression and extend the number of divisions past that limit, with a secondary proposed action on pineal function and melatonin output. A third targets NAD+ availability by inhibiting the enzyme that methylates nicotinamide and diverts it away from NAD+ salvage. NAD+ is a substrate for sirtuins and a central currency of cellular energy metabolism, and its decline with age is a well-described observation. Honesty about this pathway is essential. Senescence biology is real and actively researched, and the molecular interactions described above have been characterised in cells and rodents. What is missing is human evidence. There are no controlled clinical trials demonstrating that any of these compounds slow ageing, extend healthy lifespan, or improve any clinical outcome in people. Deliberately inducing apoptosis or manipulating telomerase activity also carries theoretical risks that have not been characterised in humans, since telomerase reactivation is a feature of many cancers. None of these compounds is approved anywhere, and all are sold as unregulated research material.

Short peptides hypothesized to enter cells and influence tissue-specific gene expression.

This group is defined by a shared hypothesis rather than a shared receptor, and the hypothesis is what makes it unusual. The peptide bioregulator concept originated in a single research programme in Russia beginning in the 1970s, initially with peptide extracts prepared from animal organs and later with very short synthetic peptides, typically two to four amino acids, said to reproduce the extracts' activity. The proposal is that these peptides are small enough to cross both the cell membrane and the nuclear envelope without a dedicated transporter, bind directly to DNA promoter regions or to histones, alter chromatin accessibility, and thereby switch on genes that have become silenced with age. Each peptide is claimed to be tissue-specific, acting on the organ its parent extract came from, so a thymus-derived preparation is proposed to act on immune tissue, a pineal-derived one on the pineal gland, and so on. Supporting observations cited by the originating group include reports that some of these peptides bind oligonucleotides in biophysical assays, that fluorescently labelled versions enter the nuclei of cultured cells, and that microarray studies show altered gene expression in treated animal tissues. Reported downstream effects vary by peptide and include changes in immune cell populations, antioxidant enzyme expression, apoptosis markers, and neurotransmitter-related gene expression. The honest assessment must be direct, because this pathway is unusually vulnerable to overstatement. Almost all of the mechanistic and outcome evidence originates from the same laboratory and its close collaborators, published substantially in Russian-language or low-circulation journals, and it has not been independently replicated by unaffiliated groups. Sequence-specific DNA binding by a two-, three-, or four-residue peptide is chemically difficult to reconcile with what is known about how transcription factors achieve specificity, since recognition of a unique genomic site generally requires a much larger binding surface. Longevity and health claims attached to these compounds frequently rest on studies that were not blinded, not randomised, or not controlled, and that were conducted by the same group that developed the products. None of these compounds is an approved medicine in the United States, the European Union, or the United Kingdom, though some have regulatory status in Russia and neighbouring countries. Material sold internationally is unregulated. The proposed mechanism should be understood as an unconfirmed hypothesis, not an established pathway.

Telomere claims rest on limited/older work; not established in rigorous human trials.

Lifespan extension is speculative and unproven in humans.